NCT00517218View on ClinicalTrials.gov

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2006

Study Completion Date

June 30, 2009

Conditions

Lymphocytic Leukemia

Interventions

DRUG

Genasense® (, oblimersen sodium G3139)

Sponsors

Lead Sponsor

Genta Incorporated

All Listed Sponsors

lead

Genta Incorporated

INDUSTRY

NCT00517218 - This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) | Biotech Hunter | Biotech Hunter